BTIG Remains Positive on NeoGenomics (NEO) Following Q4 Results, Guidance; Affirms at 'Buy'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. S
10. COF

Go back to BTIG Remains Positive on NeoGenomics (NEO) Following Q4 Results, Guidance; Affirms at 'Buy'

NeoGenomics Reports Record Revenue of $27.2 Million and Record Adjusted EBITDA of $2.9 Million in Fourth Quarter, Driven by Strong Volume Gains

March 1, 2016 7:01 AM EST

FT. MYERS, Fla., March 1, 2016 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2015.

Fourth Quarter 2015 Highlights:

25% growth in base(1) test volume 12% reduction in Avg. Cost-per-test in base(1) business Record Adjusted EBITDA(2) of $2.9 million (even with $2.1 million of FISH reductions) Adjusted Diluted EPS(2) of $0.05 per share and Diluted EPS of ($0.03) per share

Full Year 2015 Highlights:

25% growth... More